Loading
Alzheimer Dementia / Huperzine A Controlled-Release Tablets / Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets · Phase 2/3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a study registration documenting a planned Phase 2/3 trial comparing huperzine A controlled-release tablets to donepezil and placebo in mild-to-moderate Alzheimer's dementia. The trial uses a rigorous double-blind, double-dummy, active-controlled design with cognitive and functional endpoints at 24 weeks, followed by an open-label extension to week 52. No efficacy or safety results are yet reported in this registry record.
Phase 2/3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Alzheimer Dementia; age from 50 Years; to 85 Years. Intervention: Huperzine A controlled-release tablets. Compared with: Donepezil hydrochloride tablets — Active Comparator; Huperzine A controlled-release tablets placebo; Donepezil h… — Placebo Comparator. n = 720. 1 site: China.
This is a study registration documenting a planned Phase 2/3 trial comparing huperzine A controlled-release tablets to donepezil and placebo in mild-to-moderate Alzheimer's dementia. The trial uses a rigorous double-blind, double-dummy, active-controlled design with cognitive and functional endpoints at 24 weeks, followed by an open-label extension to week 52. No efficacy or safety results are yet reported in this registry record.
This is a registry record with no results posted; efficacy and safety data are not yet reported. Effect sizes, p-values, confidence intervals, and any safety signals are not provided.
Once results are published, this trial may provide evidence on the efficacy and safety of huperzine A controlled-release tablets compared to an established comparator (donepezil) in Alzheimer's dementia. Clinicians should await published results before drawing conclusions.
This is a clinical trial registry record with no reported results; the study is actively recruiting and in Phase 2/3, so only design and planned endpoints are documented.
As stated by the source record.
Quoted from the source exactly as published.
Once results are published, this trial may provide evidence on the efficacy and safety of huperzine A controlled-release tablets compared to an established comparator (donepezil) in Alzheimer's dementia. Clinicians should await published results before drawing conclusions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07066826). This is a study registration, not published results. Lead sponsor: Wanbangde Pharmaceutical Group Co., LTD. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 720 participants (ESTIMATED). Conditions: Alzheimer Dementia. Interventions: DRUG: Huperzine A Controlled-Release Tablets; DRUG: Donepezil hydrochloride tablets; DRUG: Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo. Primary outcome measures: ADAS-Cog11 , week24; ADCS-ADL , week24. Brief summary: This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial. The dose confirmation stage is designed to evaluate the efficacy and safety of different doses of huperzine A controlled-release tablets in patients with mild-to-moderate dementia of the Alzheimer's type, with the goal of providing a basis for dose selection in the subsequent efficacy confirmation stage. The efficacy confirmation stage aims to assess the effect of huperzine A controlled-release tablets on cognitive function and functional abilities in patients with mild-to-moderate dementia of the Alzheimer's type.In the open-label extension stage, all subjects will receive huperzine A controlled-release tablets until Week 52, to further evaluate the long-term efficacy and safety of the treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.